Clinical Cancer Research CR Surrogrates Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dote, H.
Right arrow Articles by Shimizu, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dote, H.
Right arrow Articles by Shimizu, N.
Clinical Cancer Research Vol. 10, 2082-2089, March 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Aberrant Promoter Methylation in Human DAB2 Interactive Protein (hDAB2IP) Gene in Breast Cancer

Hideaki Dote1, Shinichi Toyooka1, Kazunori Tsukuda1, Masaaki Yano1, Mamoru Ouchida2, Hiroyoshi Doihara1, Makoto Suzuki3, Hong Chen5, Jer-Tsong Hsieh5, Adi F. Gazdar3,4 and Nobuyoshi Shimizu1

1 Departments of Cancer and Thoracic Surgery and 2 Molecular Genetics, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan, and 3 Hamon Center for Therapeutic Oncology Research and 4 Departments of Pathology and 5 Urology, University of Texas Southwestern Medical Center, Dallas, Texas

Purpose: Human DOC-2/DAB2 interactive protein (hDAB2IP) gene is a novel member of the Ras GTPase-activating family and has been demonstrated to be a tumor suppressor gene inactivated by methylation in prostate cancer. We analyzed methylation and expression status of hDAB2IP in breast cancer.

Experimental Design: The promoter region of hDAB2IP was divided into two regions (m2a and m2b) following our previous report on prostate cancer, and methylation status was determined in breast cancer cell lines with bisulfited DNA sequencing. Expression was semiquantified with real-time reverse transcription-PCR to find that aberrant methylation showed the inverse relationship with expression. On the basis of sequence data, we developed methylation-specific PCR for m2a and m2b regions and applied to samples.

Results: Aberrant methylation was detected in 11 of 25 breast cancer cell lines (44%) and 15 of 39 primary tumors (38%) at the m2a region and in 12 of 25 cell lines (48%) and 13 of 39 tumors (33%) at the m2b region. In addition, gene expression was restored in methylated cell lines with 5-aza-2'-deoxycytidine, confirming that methylation caused gene down-regulation. We also examined the relationship between hDAB2IP methylation and clinicopathologic features in primary tumors and found that methylation in the m2b region was associated with progressive nodal status of tumors.

Conclusions: We developed methylation-specific PCR for hDAB2IP and examined its methylation status in breast cancer. Our results demonstrate that hDAB2IP methylation frequently is present in breast cancer and plays a key role in hDAB2IP inactivation, suggesting the relationship between hDAB2IP methylation and lymph node metastasis of breast cancer.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Misawa, Y. Ueda, T. Kanazawa, Y. Misawa, I. Jang, J. C. Brenner, T. Ogawa, S. Takebayashi, R. A. Grenman, J. G. Herman, et al.
Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck Cancer
Clin. Cancer Res., December 1, 2008; 14(23): 7604 - 7613.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
J.-T. Hsieh, J. A. Karam, and W. Min
Genetic and Biologic Evidence that Implicates a Gene in Aggressive Prostate Cancer
J Natl Cancer Inst, December 19, 2007; 99(24): 1823 - 1824.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Jin, X. Wang, J. Ying, A. H. Y. Wong, Y. Cui, G. Srivastava, Z.-Y. Shen, E.-M. Li, Q. Zhang, J. Jin, et al.
Epigenetic silencing of a Ca2+-regulated Ras GTPase-activating protein RASAL defines a new mechanism of Ras activation in human cancers
PNAS, July 24, 2007; 104(30): 12353 - 12358.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. T. Engelmark, E. L. Ivansson, J. J. Magnusson, I. M. Gustavsson, A. H. Beskow, P. K.E. Magnusson, and U. B. Gyllensten
Identification of susceptibility loci for cervical carcinoma by genome scan of affected sib-pairs
Hum. Mol. Genet., November 15, 2006; 15(22): 3351 - 3360.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. Chen, S.-w. Tu, and J.-T. Hsieh
Down-regulation of Human DAB2IP Gene Expression Mediated by Polycomb Ezh2 Complex and Histone Deacetylase in Prostate Cancer
J. Biol. Chem., June 10, 2005; 280(23): 22437 - 22444.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.